• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cryoport to Host Investor Call to Discuss Recent Strategic Agreement and Transformative Transaction Today, March 31, 2025, at 8:30 a.m. ET

    3/31/25 8:09:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYRX alert in real time by email

    NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences sector, today announced that the Company will host an investor call today, Monday, March 31, 2025, at 8:30 a.m. ET, to discuss the Company's recent strategic agreement and transformative transaction, which includes a strategic partnership with the DHL Group (DHL) and DHL's acquisition of CRYOPDP

    Cryoport logo 2024

    The conference call will include remarks by the management team followed by a questions and answers session that will address questions members of the investment community have regarding these recent events. A slide deck will accompany the call.

    Conference Call Information

    Date:

    Monday, March 31, 2025

    Time:

    8:30 a.m. ET, 4:30 PM (UTC+1)

    Dial-in numbers:

    1-800-717-1738 (U.S.), 1-646-307-1865 (International)

    Confirmation code:

    Request the "Cryoport Call" or Conference ID: 1197941

    Live webcast:

    'Investor Relations' section at www.cryoportinc.com or click here.

     

    Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

    The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until April 7, 2025. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1197941#.

    About Cryoport, Inc

    Cryoport, Inc. (NASDAQ:CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.

    Our corporate headquarters, located in Nashville, Tennessee, is complemented by over 50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the Netherlands, Belgium, Portugal, Germany, Japan, Australia, India, and China.

    For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.

    Forward-Looking Statements

    Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the sale of CRYOPDP and the strategic collaboration with DHL, including the potential impact on future revenue and revenue streams.  It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-to-host-investor-call-to-discuss-recent-strategic-agreement-and-transformative-transaction-today-march-31-2025-at-830-am-et-302415562.html

    SOURCE Cryoport, Inc.

    Get the next $CYRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYRX

    DatePrice TargetRatingAnalyst
    8/6/2025Sector Weight → Overweight
    KeyBanc Capital Markets
    8/6/2025$16.00Market Perform → Outperform
    Leerink Partners
    7/22/2025$13.00Overweight
    Stephens
    3/24/2025$10.00Neutral → Buy
    UBS
    12/19/2024$11.00Buy
    Guggenheim
    12/19/2024$11.00Buy
    Canaccord Genuity
    8/7/2024$20.00 → $8.00Buy → Hold
    Jefferies
    7/31/2024$19.00 → $15.00Neutral → Buy
    B. Riley Securities
    More analyst ratings

    $CYRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cryoport upgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets upgraded Cryoport from Sector Weight to Overweight

    8/6/25 7:50:22 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Cryoport from Market Perform to Outperform and set a new price target of $16.00

    8/6/25 7:21:40 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens resumed coverage on Cryoport with a new price target

    Stephens resumed coverage of Cryoport with a rating of Overweight and set a new price target of $13.00

    7/22/25 7:52:13 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

    FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidanceLife Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y)NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for th

    3/3/26 4:05:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business upd

    2/17/26 8:00:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

    Self-Sustaining Fusion® 800 Series Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced the launch of the MVE Fusion® 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology. This self-sustaining cryogenic freezer eliminates the need for a continuous liquid nitrogen (LN₂) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designe

    2/11/26 8:30:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mandalam Ramkumar sold $115,540 worth of shares (11,570 units at $9.99), decreasing direct ownership by 13% to 80,758 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    12/12/25 5:30:13 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hariri Robert J exercised 50,000 shares at a strike of $2.66 and sold $242,738 worth of shares (25,000 units at $9.71), increasing direct ownership by 95% to 51,275 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    9/12/25 5:30:14 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hariri Robert J sold $43,000 worth of shares (5,000 units at $8.60), decreasing direct ownership by 16% to 26,275 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    8/29/25 6:46:12 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    SEC Filings

    View All

    SEC Form 10-K filed by CryoPort Inc.

    10-K - Cryoport, Inc. (0001124524) (Filer)

    3/5/26 4:53:43 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CryoPort Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cryoport, Inc. (0001124524) (Filer)

    3/3/26 5:10:46 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.

    SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)

    2/17/26 5:00:26 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CryoPort Inc.

    SC 13G - Cryoport, Inc. (0001124524) (Subject)

    11/14/24 4:02:52 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

    SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

    11/14/24 1:34:13 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

    SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

    11/13/24 7:16:51 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Financials

    Live finance-specific insights

    View All

    Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

    FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidanceLife Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y)NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for th

    3/3/26 4:05:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business upd

    2/17/26 8:00:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport Reports Third Quarter 2025 Financial Results

    Third quarter revenue increased 15% year-over-year to $44.2 millionCommercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 millionLife Sciences Services revenue grew 16% year-over-year, including a 21% rise in BioStorage/BioServices revenue Life Sciences Products revenue grew 15% year-over-yearCompany updates full year 2025 revenue guidance of $170 to $174 millionNASHVILLE, Tenn., Nov. 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2025. Provided in

    11/4/25 4:05:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Leadership Updates

    Live Leadership Updates

    View All

    Moffitt Cancer Center and Cryoport Announce Strategic Collaboration

    Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, and Cryoport, Inc. (NASDAQ:CYRX), a global leader in supply chain solutions for the life sciences industry, today announced a strategic collaboration that will provide CRYOGENE's state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport's CRYOGENE business unit is a leading biorepository for the life sciences industry that i

    1/14/25 8:30:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport Announces Appointment of Linda Baddour to its Board of Directors

    NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the Board, effective March 15, 2021. Linda Baddour is a senior executive with over twenty years of experience in healthcare, life sciences and pharmaceuticals. "Our corporate governance underpins all that we do at Cryoport and we are delighted to strengthen our Board as we leverage our newly expanded global footprint and advanced temperature-controlled supply chain platform to spur our growth," said Jerrell She

    3/3/21 4:08:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Appoints Martin Schmieg to Board of Directors

    BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, L

    12/1/20 6:30:00 AM ET
    $BCTX
    $CLBS
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Managed Health Care